Intangible Assets

NDRA appears to have limited intangible asset protection because the provided metrics show deeply negative ROIC and ROCE, which implies any proprietary know-how is not translating into durable economic returns versus peers.

No evidence in the supplied data indicates meaningful brand, regulatory, or IP-based pricing power, so competitors likely face few barriers to offering substitute solutions.

Compared with stronger medtech peers that sustain premium margins through validated clinical data, NDRA’s current profitability profile suggests its intangible assets are not yet a durable moat.

The absence of positive long-run margin or return evidence makes any customer willingness to pay a premium look weak and not durable over a 5–10 year horizon.

Switching Costs

The negative ROIC and ROCE imply customers are not locked in by high switching costs, because the business is not retaining enough value to show durable renewal economics versus peers.

No supplied evidence points to workflow integration, regulatory lock-in, or mission-critical embedded usage that would make replacement costly for customers.

Relative to peers with installed-base service models or recurring consumables, NDRA’s current financial profile does not show the retention or pricing stickiness that usually signals switching costs.

The extremely weak cash conversion cycle does not indicate a stable, high-retention customer base that would support durable switching friction.

Network Effects

The provided data do not show any user, data, or ecosystem flywheel that would cause each additional customer to make the product more valuable for others.

Unlike platform peers where adoption compounds through shared data or interoperability, NDRA’s current metrics do not evidence self-reinforcing demand or peer-dependent usage.

Negative returns and absent scale indicators suggest the company is not yet operating a network-driven model that could strengthen pricing power over time.

There is no evidence in the supplied information that NDRA’s competitive position improves as installed base expands, so network effects appear negligible.

Cost Advantage

NDRA’s negative ROIC and ROCE indicate it is not converting capital into returns efficiently enough to suggest a structural cost advantage versus peers.

No evidence in the supplied metrics shows superior unit economics, manufacturing leverage, or procurement scale that would let NDRA underprice competitors sustainably.

Compared with lower-cost peers that can defend share through margin resilience, NDRA’s current profile suggests it is not operating with a durable cost edge.

The lack of positive operating efficiency evidence means any cost advantage is either absent or too small to support long-term moat durability.

Efficient Scale

The supplied data do not indicate that NDRA serves a niche large enough to support efficient scale, because there is no evidence of monopoly-like economics or stable excess returns.

Negative returns and zero asset turnover suggest the business is not yet extracting the fixed-cost leverage that would make a small market structurally attractive versus peers.

Unlike peers in regulated or capacity-constrained niches, NDRA does not show evidence of an industry structure that limits room for multiple profitable competitors.

The current financial profile implies that scale is not yet creating durable competitive insulation, so efficient scale appears weak.

Overall Score

NDRA shows no clear evidence of a durable economic moat versus peers, because the supplied metrics point to deeply negative capital returns, weak efficiency, and no observable switching, network, cost, or scale advantages that would sustain pricing power or retention over 5–10 years.